Augusto Villanueva

List of PR Articles by Year
in descending order

120 PR articles	27,173 PR citations	8087 66 PR h-index	11827 120 g-index
141 documents	31532 doc citations	8682 71 h-index	30255 citing authors

#	Article	IF	PR Citations
1	Novel biomarkers and strategies for HCC diagnosis and care. Clinical Liver Disease, 2024, 23, .	1.4	2
2	Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut, 2023, 72, 129-140.	21.2	194
3	Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut, 2023, 72, 736-748.	21.2	120
4	WNTinib is a multi-kinase inhibitor with specificity against Î²-catenin mutant hepatocellular carcinoma. Nature Cancer, 2023, 4, 1157-1175.	22.8	23
5	Biomarkers for immunotherapy of hepatocellular carcinoma. Nature Reviews Clinical Oncology, 2023, 20, 780-798.	75.5	164
6	Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer. Gut, 2022, 71, 2069-2080.	21.2	39
7	Digital-resolution and highly sensitive detection of multiple exosomal small RNAs by DNA toehold probe-based photonic resonator absorption microscopy. Talanta, 2022, 241, 123256.	5.9	26
8	Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Molecular Oncology, 2022, 16, 665-682.	4.2	9
9	Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. Clinical Cancer Research, 2022, 28, 2297-2305.	6.9	13
10	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nature Cancer, 2022, 3, 386-401.	22.8	382
11	Biomarker Development Using Liquid Biopsy in Hepatocellular Carcinoma. Seminars in Liver Disease, 2022, 42, 188-201.	3.4	10
12	DNA Methylation Profiling of Human Hepatocarcinogenesis. Hepatology, 2021, 74, 183-199.	10.6	82
13	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology, 2021, 73, 158-191.	10.6	342
14	Biomarkers for Hepatobiliary Cancers. Hepatology, 2021, 73, 115-127.	10.6	136
15	The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication. Cancers, 2021, 13, 659.	4.0	41
16	Experimental Models of Liquid Biopsy in Hepatocellular Carcinoma Reveal Cloneâ€Dependent Release of Circulating Tumor DNA. Hepatology Communications, 2021, 5, 1095-1105.	4.7	7
17	Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma. PLoS Genetics, 2021, 17, e1009589.	3.3	20
18	Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis. JHEP Reports, 2021, 3, 100237.	4.8	58

#	Article	IF	PR Citations
19	Novel non-protein biomarkers for early detection of hepatocellular carcinoma. Engineering, 2021, , .	7.9	2
20	Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002â€“2020). Gastroenterology, 2021, 161, 879-898.	1.0	209
21	Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B. JHEP Reports, 2021, 3, 100364.	4.8	22
22	Hepatocellular carcinoma. Nature Reviews Disease Primers, 2021, 7, .	50.7	5,235
23	Hypomethylation in HBV integration regions aids non-invasive surveillance to hepatocellular carcinoma by low-pass genome-wide bisulfite sequencing. BMC Medicine, 2020, 18, .	7.5	34
24	Liquid biopsy in the clinical management of hepatocellular carcinoma. Gut, 2020, 69, 2025-2034.	21.2	107
25	Tumor fitness, immune exhaustion and clinical outcomes: impact of immune checkpoint inhibitors. Scientific Reports, 2020, 10, .	3.5	6
26	Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. Journal of Hepatology, 2020, 73, 315-327.	3.6	257
27	Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma. Liver Transplantation, 2020, 26, 823-831.	2.6	34
28	Intratumoral heterogeneity and clonal evolution in liver cancer. Nature Communications, 2020, 11, .	13.9	318
29	Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. Oncogene, 2020, 40, 140-151.	6.7	112
30	Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut, 2019, 68, 1065-1075.	21.2	287
31	Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. British Journal of Cancer, 2019, 121, 340-343.	5.7	78
32	Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. Cancer Research, 2019, 79, 4326-4330.	0.6	137
33	Mechanisms of Action of Drugs Effective in Hepatocellular Carcinoma. Clinical Liver Disease, 2019, 14, 62-65.	1.4	25
34	A phenotypical map of disseminated hepatocellular carcinoma suggests clonal constraints in metastatic sites. Histopathology, 2019, 74, 718-730.	3.7	10
35	Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology. Molecular Cancer Therapeutics, 2019, 18, 1506-1519.	1.8	20
36	The oncogenic role of hepatitis delta virus in hepatocellular carcinoma. JHEP Reports, 2019, 1, 120-130.	4.8	67

#	Article	IF	PR Citations
37	Î²-Catenin Activation Promotes Immune Escape and Resistance to Antiâ€“PD-1 Therapy in Hepatocellular Carcinoma. Cancer Discovery, 2019, 9, 1124-1141.	25.6	770
38	Mannose Phosphate Isomerase and Mannose Regulate Hepatic Stellate Cell Activation and Fibrosis in Zebrafish and Humans. Hepatology, 2019, 70, 2107-2122.	10.6	30
39	Parity predisposes breasts to the oncogenic action of PAPP-A and activation of the collagen receptor DDR2. Breast Cancer Research, 2019, 21, .	4.9	22
40	Hepatocellular Carcinoma. New England Journal of Medicine, 2019, 380, 1450-1462.	43.7	3,948
41	The Impact of Translational Research in Hepatology. Clinical Liver Disease, 2019, 13, 29-33.	1.4	2
42	Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. Journal of Hepatology, 2019, 70, 1262-1277.	3.6	199
43	Tumour evolution in hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2019, 17, 139-152.	48.0	707
44	A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene, 2018, 37, 3740-3752.	6.7	102
45	Role of circulating tumor DNA to help decision-making in hepatocellular carcinoma. Oncoscience, 2018, 5, 209-211.	1.3	12
46	High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma. Scientific Reports, 2018, 8, .	3.5	74
47	Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. Gut, 2017, 66, 530-540.	21.2	187
48	Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. Journal of Hepatology, 2017, 66, 952-961.	3.6	151
49	Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology, 2017, 153, 812-826.	1.0	815
50	Liver Cancer Cell of Origin, Molecular Class, and Effects onÂPatient Prognosis. Gastroenterology, 2017, 152, 745-761.	1.0	1,029
51	Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. Journal of Hepatology, 2017, 67, 1222-1231.	3.6	151
52	Natural history of nonalcoholic steatohepatitis/nonalcoholic fatty liver diseaseâ€hepatocellular carcinoma: Magnitude of the problem from a hepatology clinic perspective. Clinical Liver Disease, 2016, 8, 100-104.	1.4	21
53	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. Cancer Cell, 2016, 30, 879-890.	38.5	194
54	The transition from inflammation to cancer in the liver. Clinical Liver Disease, 2016, 8, 89-93.	1.4	34

#	Article	IF	PR Citations
55	IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. Gastroenterology, 2016, 151, 1192-1205.	1.0	116
56	Genetic profiling of hepatocellular carcinoma using next-generation sequencing. Journal of Hepatology, 2016, 65, 1031-1042.	3.6	271
57	Liver capsule: Molecularâ€based signatures in hepatocellular carcinoma. Hepatology, 2016, 63, 2018-2018.	10.6	9
58	A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. Gut, 2016, 65, 1754-1764.	21.2	125
59	Clinical Trial Watch: Reports from the Liver MeetingÂ®, AASLD, San Francisco, November 2015. Journal of Hepatology, 2016, 64, 1428-1445.	3.6	3
60	Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nature Reviews Clinical Oncology, 2015, 12, 408-424.	75.5	513
61	DNA methylationâ€based prognosis and epidrivers in hepatocellular carcinoma. Hepatology, 2015, 61, 1945-1956.	10.6	420
62	Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma. Gastroenterology, 2015, 148, 806-818.e10.	1.0	118
63	Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology, 2015, 149, 1226-1239.e4.	1.0	1,171
64	Clinical Trial Watch: Reports from the EASL International Liver Congress (ILC), Vienna, April 2015. Journal of Hepatology, 2015, 63, 753-762.	3.6	5
65	DNA-PKâ€"A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival. Clinical Cancer Research, 2015, 21, 925-933.	6.9	80
66	Intratumor Molecular and Phenotypic Diversity in Hepatocellular Carcinoma. Clinical Cancer Research, 2015, 21, 1786-1788.	6.9	84
67	The Future of Patient-Derived Tumor Xenografts in Cancer Treatment. Pharmacogenomics, 2015, 16, 1671-1683.	1.6	46
68	A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut, 2015, 64, 1296-1302.	21.2	75
69	The usual SASPects of liver cancer. Aging, 2015, 7, 348-349.	2.5	5
70	UHRF1 Overexpression Drives DNA Hypomethylation and Hepatocellular Carcinoma. Cancer Cell, 2014, 25, 196-209.	38.5	288
71	VEGF Signaling in Cancer Treatment. Current Pharmaceutical Design, 2014, 20, 2834-2842.	2.4	83
72	Prognostic Gene Expression Signature for Patients With Hepatitis Câ€"Related Early-Stage Cirrhosis. Gastroenterology, 2013, 144, 1024-1030.	1.0	217

#	Article	IF	PR Citations
73	Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated withEGFR. Hepatology, 2013, 57, 120-130.	10.6	54
74	Rethinking future development of molecular therapies in hepatocellular carcinoma: A bottom-up approach. Journal of Hepatology, 2013, 59, 392-395.	3.6	20
75	Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes. Gastroenterology, 2013, 144, 829-840.	1.0	505
76	A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection. Gastroenterology, 2013, 145, 176-187.	1.0	317
77	Management of small hepatocellular carcinoma in cirrhosis: Focus on portal hypertension. World Journal of Gastroenterology, 2013, 19, 1193.	4.8	35
78	Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma. Hepatology, 2012, 56, 2416-2419.	10.6	16
79	Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib. Clinical Cancer Research, 2012, 18, 4997-5007.	6.9	284
80	Cell population genetics and deep sequencing: A novel approach for drivers discovery in hepatocellular carcinoma. Journal of Hepatology, 2012, 56, 1198-1200.	3.6	3
81	Molecular epidemiology in HCV-related hepatocellular carcinoma: First steps. Journal of Hepatology, 2012, 57, 213-214.	3.6	6
82	Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. Journal of Hepatology, 2012, 56, 1343-1350.	3.6	196
83	Why men are at higher risk for hepatocellular carcinoma?. Journal of Hepatology, 2012, 57, 453-454.	3.6	48
84	PronÃ³stico genÃ³mico en el carcinoma hepatocelular. GastroenterologÃa Y HepatologÃa, 2012, 35, 94-101.	0.6	2
85	Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib. Clinical Cancer Research, 2012, 18, 1824-1826.	6.9	88
86	Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. Hepatology, 2012, 56, 1361-1370.	10.6	34
87	Notch Signaling Is Activated in Human Hepatocellular Carcinoma and Induces Tumor Formation in Mice. Gastroenterology, 2012, 143, 1660-1669.e7.	1.0	296
88	Gene Signatures in the Management of Hepatocellular Carcinoma. Seminars in Oncology, 2012, 39, 473-485.	1.9	70
89	Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nature Reviews Gastroenterology and Hepatology, 2012, 10, 34-42.	48.0	290
90	Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma. Gastroenterology, 2011, 140, 1501-1512.e2.	1.0	420

#	Article	IF	PR Citations
91	MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a. Gastroenterology, 2011, 140, 1618-1628.e16.	1.0	212
92	Targeted Therapies for Hepatocellular Carcinoma. Gastroenterology, 2011, 140, 1410-1426.	1.0	429
93	Gene-expression signature of vascular invasion in hepatocellular carcinoma. Journal of Hepatology, 2011, 55, 1325-1331.	3.6	140
94	Depicting the role of TP53 in hepatocellular carcinoma progression. Journal of Hepatology, 2011, 55, 724-725.	3.6	63
95	Molecular Pathogenesis of Hepatocellular Carcinoma. Alcoholism: Clinical and Experimental Research, 2011, 35, 821-825.	2.6	48
96	Carcinogen-induced hepatic tumors in KLF6+/â˜' mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Hepatology, 2011, 54, 522-531.	10.6	42
97	Inherited hepatocellular carcinoma. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 725-734.	3.0	28
98	New Strategies in Hepatocellular Carcinoma: Genomic Prognostic Markers. Clinical Cancer Research, 2010, 16, 4688-4694.	6.9	116
99	Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements. Seminars in Liver Disease, 2010, 30, 035-051.	3.4	280
100	Cancer gene discovery in hepatocellular carcinoma. Journal of Hepatology, 2010, 52, 921-929.	3.6	179
101	IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. Journal of Hepatology, 2010, 52, 550-559.	3.6	215
102	Genomic tracing of the elusive liver cancer ancestor. Journal of Hepatology, 2010, 53, 578-579.	3.6	1
103	Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy. Annual Review of Medicine, 2010, 61, 317-328.	19.5	242
104	Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma. Cancer Research, 2009, 69, 7385-7392.	0.6	1,131
105	A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nature Biotechnology, 2009, 27, 264-274.	32.2	199
106	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. Journal of Hepatology, 2009, 51, 725-733.	3.6	213
107	Pathogenesis of hepatocellular carcinoma and molecular therapies. Current Opinion in Gastroenterology, 2009, 25, 186-194.	2.3	121
108	Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. Journal of Clinical Investigation, 2009, 119, 465-477.	10.7	307

#	Article	IF	PR Citations
109	Ras Promotes Growth by Alternative Splicing-Mediated Inactivation of the KLF6 Tumor Suppressor in Hepatocellular Carcinoma. Gastroenterology, 2008, 134, 1521-1531.	1.0	99
110	Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma. Gastroenterology, 2008, 135, 1972-1983.e11.	1.0	680
111	Experimental models of hepatocellular carcinoma. Journal of Hepatology, 2008, 48, 858-879.	3.6	211
112	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Molecular Cancer Therapeutics, 2008, 7, 3129-3140.	1.8	1,346
113	Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. New England Journal of Medicine, 2008, 359, 1995-2004.	43.7	1,201
114	Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Current Opinion in Oncology, 2008, 20, 444-453.	2.2	61
115	Genomics and Signaling Pathways in Hepatocellular Carcinoma. Seminars in Liver Disease, 2007, 27, 055-076.	3.4	499
116	Current management of liver cancer. European Journal of Cancer, Supplement, 2007, 5, 444-446.	0.5	4
117	BiologÃa celular y genÃ©tica en el cÃ¡ncer de hÃgado. GastroenterologÃa Y HepatologÃa, 2007, 30, 360-369.	0.6	5
118	A Molecular Signature to Discriminate Dysplastic Nodules From Early Hepatocellular Carcinoma in HCV Cirrhosis. Gastroenterology, 2006, 131, 1758-1767.	1.0	385
119	Accuracy of plasma levels of polymorphonuclear elastase as early prognostic marker of acute pancreatitis in routine clinical conditions. European Journal of Gastroenterology and Hepatology, 2006, 18, 79-83.	1.4	24
120	Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: A critical appraisal. Liver Transplantation, 2006, 12, 1747-1754.	2.6	17